Nelarabine
Back to searchMolecule Structure
Scientific Name
Nelarabine
Description of the Drug
Nelarabine is a purine nucleoside analog and antineoplastic agent used for the treatment of with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma with inadequate clinical response to prior chemotherapeutic treatments.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01280
http://www.drugbank.ca/drugs/DB01280
Brand Name(s)
Arranon, Atriance
Company Owner(s)
Zydus Pharmaceuticals Usa Inc, Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL18820 | |
PharmGKB | PA164752425 | |
Human Metabolome Database | HMDB0015401 | |
DrugBank | DB01280 | |
PubChem: Thomson Pharma | 14775959 | 14922755 |
PubChem | 3011155 | |
LINCS | LSM-45931 | |
Nikkaji | J679.698B | |
BindingDB | 50247985 | |
EPA CompTox Dashboard | DTXSID6046842 | |
DrugCentral | 1892 | |
ChemicalBook | CB01011878 | |
Guide to Pharmacology | 7090 | |
rxnorm | ARRANON | NELARABINE |
PubChem: Drugs of the Future | 12015013 | |
ChEBI | 63612 | |
ZINC | ZINC000003823492 |